Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Laura F van der Voort"'
Autor:
Lisa G M van Baarsen, Saskia Vosslamber, Marianne Tijssen, Josefien M C Baggen, Laura F van der Voort, Joep Killestein, Tineke C T M van der Pouw Kraan, Chris H Polman, Cornelis L Verweij
Publikováno v:
PLoS ONE, Vol 3, Iss 4, p e1927 (2008)
BackgroundMultiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy.MethodologyLarge scale gene expressi
Externí odkaz:
https://doaj.org/article/540228089a5342948db5eca8f6d61378
Autor:
Thang V. Pham, Laura F. van der Voort, Charlotte E. Teunissen, Connie R. Jimenez, Marleen J. A. Koel-Simmelink
Publikováno v:
Jimenez, C R, Koel-Simmelink, M, Pham, T V, van der Voort, L & Teunissen, C E 2007, ' Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry : Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables ', Proteomics-Clinical Applications, vol. 1, no. 11, pp. 1385-1392 . https://doi.org/10.1002/prca.200700330
Proteomics-Clinical Applications, 1(11), 1385-1392. Wiley-VCH Verlag
Proteomics-Clinical Applications, 1(11), 1385-1392. Wiley-VCH Verlag
Cerebrospinal fluid (CSF) perfuses the brain and spinal cord. CSF contains peptides and proteins important for brain physiology and potentially also relevant to brain pathology. High-throughput endogeneous peptide profiling by MS is an emerging appro
Autor:
Joep Killestein, Chris H. Polman, Dirk L. Knol, Laura F. van der Voort, Francesca Gilli, Bernard M. J. Uitdehaag, Antonio Bertolotto
Publikováno v:
van der Voort, L F, Gilli, F, Bertolotto, A, Knol, D L, Uitdehaag, B M J, Polman, C H & Killestein, J 2010, ' Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis ', Archives of Neurology, vol. 67, no. 4, pp. 402-407 . https://doi.org/10.1001/archneurol.2010.21
Archives of Neurology, 67(4), 402-407. American Medical Association
Archives of Neurology, 67(4), 402-407. American Medical Association
Objectives: To confirm that neutralizing antibodies (NAb) to interferon beta can persist after therapy withdrawal and to evaluate whether persisting NAb are associated with a worse clinical disease course in multiple sclerosis (MS). Design: Retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54c031e8124b99815694ec9670d93e3
https://hdl.handle.net/1871.1/6318826b-8b78-452f-9648-b7ba1d4395a5
https://hdl.handle.net/1871.1/6318826b-8b78-452f-9648-b7ba1d4395a5
Autor:
Rodrigo Naves, Patrizia De Sarno, Roopa Bhat, Katia Boniface, Liat Katz, Athena Christakos, Chris H. Polman, Robert D. Mair, Rene de Waal Malefyt, Joep Killestein, Ilan Kolkowitz, Laura F van der Voort, Jim G Castellanos, Chander Raman, Lawrence Steinman, Franklin L. Zhong, May H. Han, Brigit A. de Jong, Robert C. Axtell
Publikováno v:
Nature Medicine, 16(4), 406-U21. Nature Publishing Group
Axtell, R C, de Jong, B A, Boniface, K, van der Voort, L F, Bhat, R, De Sarno, P, Naves, R, Han, M, Zhong, F, Castellanos, J G, Mair, R, Christakos, A, Kolkowitz, I, Katz, L, Killestein, J, Polman, C H, Malefyt, R D, Steinman, L & Raman, C 2010, ' T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis ', Nature Medicine, vol. 16, no. 4, pp. 406-U21 . https://doi.org/10.1038/nm.2110
Nature Medicine, 16, 4, pp. 406-12
Nature Medicine, 16, 406-12
Axtell, R C, de Jong, B A, Boniface, K, van der Voort, L F, Bhat, R, De Sarno, P, Naves, R, Han, M, Zhong, F, Castellanos, J G, Mair, R, Christakos, A, Kolkowitz, I, Katz, L, Killestein, J, Polman, C H, Malefyt, R D, Steinman, L & Raman, C 2010, ' T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis ', Nature Medicine, vol. 16, no. 4, pp. 406-U21 . https://doi.org/10.1038/nm.2110
Nature Medicine, 16, 4, pp. 406-12
Nature Medicine, 16, 406-12
Item does not contain fulltext Interferon-beta (IFN-beta) is the major treatment for multiple sclerosis. However, this treatment is not always effective. Here we have found congruence in outcome between responses to IFN-beta in experimental autoimmun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62deab33197be21947a3d3c4556ba462
https://research.vumc.nl/en/publications/a606a610-86d8-4c73-8ec3-ab80e96e494a
https://research.vumc.nl/en/publications/a606a610-86d8-4c73-8ec3-ab80e96e494a
Autor:
Chris H. Polman, Cornelis L. Verweij, Joep Killestein, Lisa G. M. van Baarsen, J.M. Baggen, Saskia Vosslamber, Laura F. van der Voort, Tineke C. T. M. van der Pouw Kraan, Marianne Tijssen
Publikováno v:
van Baarsen, L G, Vosslamber, S, Tijssen, M, Baggen, J M, van, D V, Killestein, J, van der Pouw Kraan, C T M, Polman, C H & Verweij, C L 2008, ' Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients ', PLoS ONE, vol. 3, no. 4, pp. e1927 . https://doi.org/10.1371/journal.pone.0001927
PLoS ONE
PLoS ONE, 3(4). Public Library of Science
PLoS ONE, Vol 3, Iss 4, p e1927 (2008)
PLoS ONE
PLoS ONE, 3(4). Public Library of Science
PLoS ONE, Vol 3, Iss 4, p e1927 (2008)
Background: Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNs in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNs therapy. Methodology: Large scale gene expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f0274cf04cc648146a949e014c750c
https://research.vumc.nl/en/publications/97299801-a71b-41b7-bc16-a99471b8018b
https://research.vumc.nl/en/publications/97299801-a71b-41b7-bc16-a99471b8018b